Literature DB >> 10319873

Evolution of neoplastic cell lineages in Barrett oesophagus.

M T Barrett1, C A Sanchez, L J Prevo, D J Wong, P C Galipeau, T G Paulson, P S Rabinovitch, B J Reid.   

Abstract

It has been hypothesized that neoplastic progression develops as a consequence of an acquired genetic instability and the subsequent evolution of clonal populations with accumulated genetic errors. Accordingly, human cancers and some premalignant lesions contain multiple genetic abnormalities not present in the normal tissues from which the neoplasms arose. Barrett oesophagus (BE) is a premalignant condition which predisposes to oesophageal adenocarcinoma (EA) that can be biopsied prospectively over time because endoscopic surveillance is recommended for early detection of cancer. In addition, oesophagectomy specimens frequently contain the premalignant epithelium from which the cancer arose. Neoplastic progression in BE is associated with alterations in TP53 (also known as p53) and CDKN2A (also known as p16) and non-random losses of heterozygosity (LOH). Aneuploid or increased 4N populations occur in more than 90-95% of EAs, arise in premalignant epithelium and predict progression. We have previously shown in small numbers of patients that disruption of TP53 and CDKN2A typically occurs before aneuploidy and cancer. Here, we determine the evolutionary relationships of non-random LOH, TP53 and CDKN2A mutations, CDKN2A CpG-island methylation and ploidy during neoplastic progression. Diploid cell progenitors with somatic genetic or epigenetic abnormalities in TP53 and CDKN2A were capable of clonal expansion, spreading to large regions of oesophageal mucosa. The subsequent evolution of neoplastic progeny frequently involved bifurcations and LOH at 5q, 13q and 18q that occurred in no obligate order relative to each other, DNA-content aneuploidy or cancer. Our results indicate that clonal evolution is more complex than predicted by linear models.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319873      PMCID: PMC1559997          DOI: 10.1038/8816

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  28 in total

1.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.

Authors:  P C Galipeau; D S Cowan; C A Sanchez; M T Barrett; M J Emond; D S Levine; P S Rabinovitch; B J Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Multiple head and neck tumors: evidence for a common clonal origin.

Authors:  G C Bedi; W H Westra; E Gabrielson; W Koch; D Sidransky
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma.

Authors:  M T Barrett; M Schutte; S E Kern; B J Reid
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

4.  Genetic progression model for head and neck cancer: implications for field cancerization.

Authors:  J Califano; P van der Riet; W Westra; H Nawroz; G Clayman; S Piantadosi; R Corio; D Lee; B Greenberg; W Koch; D Sidransky
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

5.  Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

Authors:  T Kuukasjärvi; R Karhu; M Tanner; M Kähkönen; A Schäffer; N Nupponen; S Pennanen; A Kallioniemi; O P Kallioniemi; J Isola
Journal:  Cancer Res       Date:  1997-04-15       Impact factor: 12.701

6.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.

Authors:  A van der Burgh; J Dees; W C Hop; M van Blankenstein
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

7.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.

Authors:  P L Blount; P C Galipeau; C A Sanchez; K Neshat; D S Levine; J Yin; H Suzuki; J M Abraham; S J Meltzer; B J Reid
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

8.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.

Authors:  M T Barrett; C A Sanchez; P C Galipeau; K Neshat; M Emond; B J Reid
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

9.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.

Authors:  K Neshat; C A Sanchez; P C Galipeau; P L Blount; D S Levine; G Joslyn; B J Reid
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

10.  Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms.

Authors:  M T Barrett; P C Galipeau; C A Sanchez; M J Emond; B J Reid
Journal:  Oncogene       Date:  1996-05-02       Impact factor: 9.867

View more
  129 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

3.  Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?

Authors:  M A Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-10

Review 4.  Epigenetic biomarkers in esophageal cancer.

Authors:  Andrew M Kaz; William M Grady
Journal:  Cancer Lett       Date:  2012-03-07       Impact factor: 8.679

5.  Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Authors:  Rebecca E Rudolph; Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

Review 6.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

7.  Clonal origin and expansions in neoplasms: biologic and technical aspects must be considered together.

Authors:  Lucia Pozo-Garcia; Salvador J Diaz-Cano
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

8.  SCOMP is superior to degenerated oligonucleotide primed-polymerase chain reaction for global amplification of minute amounts of DNA from microdissected archival tissue samples.

Authors:  Nikolas H Stoecklein; Andreas Erbersdobler; Oleg Schmidt-Kittler; Joachim Diebold; Julian A Schardt; Jakob R Izbicki; Christoph A Klein
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 10.  Barrett esophagus: what a mouse model can teach us about human disease.

Authors:  Michael Quante; Julian A Abrams; Yoomi Lee; Timothy C Wang
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.